Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro

Molecular Medicine Reports

Volumn 4, Issue 2, 2011, Pages 343-349

  Que, Wenzhong ^a   Chen, Junmin ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

c Met; Invasion; Proliferation; Short hairpin rna; u266 cells

Indexed keywords

CASPASE 3; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE ARREST; CELL INVASION; CELL LINE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; RNA INTERFERENCE;

APOPTOSIS; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MULTIPLE MYELOMA; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-MET; RNA, SMALL INTERFERING;

EID: 79551698356     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.426     Document Type: Article

References (54)

1. Kyle RA and Rajkumar SV: Multiple myeloma. N Engl J Med 351: 1860-1873, 2004.
2. Richardson PG: A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother 5: 1321-1331, 2004.
3. Richardson PG, Mitsiades CS, Hideshima T and Anderson KC: Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol 18: 619-634, 2005. (Pubitemid 40984118)
4. Harousseau JL: Stem cell transplantation in multiple myeloma. Curr Opin Oncol 17: 93-98, 2005.
5. Ghobrial IM, Leleu X, Hatjiharissi E, et al: Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs 12: 155-163, 2007.
6. Pagnucco G, Cardinale G and Gervasi F: Targeting multiple myeloma cells and their bone marrow microenvironment. Ann N Y Acad Sci 1028: 390-399, 2004. (Pubitemid 40361840)
7. Damiano JS, Cress AE, Hazlehurst LA, et al: Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93: 1658-1667, 1999. (Pubitemid 29102494)
8. Hideshima T, Chauhan D, Hayashi T, et al: The biological sequelae of stromal cell derived factor-1 alpha in multiple myeloma. Mol Cancer Ther 1: 539-544, 2002.
9. Damiano JS and Dalton WS: Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 38: 71-81, 2000. (Pubitemid 30224324)
10. Hideshima T, Nakamura N, Chauhan D and Anderson KC: Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20: 5991-6000, 2001. (Pubitemid 32955041)
11. Hideshima T, Podar K, Chauhan D and Anderson KC: Cytokines and signal transduction. Best Pract Res Clin Haematol 18: 509-524, 2005.
12. Gupta D, Treon SP, Shima Y, et al: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15: 1950-1961, 2001.
13. Akiyama M, Hideshima T, Hayashi T, et al: cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 62: 3876-3882, 2002. (Pubitemid 34728875)
14. Roccisana J, Reddy V, Vasavada RC, et al: Targeted inactivation of hepatocyte growth facto receptor c-Met in β-cells leads to defective insulin secretion and GLUT-2 down regulation with out alter ation of β-cell mass. Diabetes 54: 2090-2102, 2005. (Pubitemid 40911272)
15. Giordano S, Ponzetto C, DiRenzo MF, et al: Tyrosine kinase receptor in distinguish able from the c-Met protein. Nature 339: 155-156, 1989. (Pubitemid 19122275)
16. Camp RL, Rimn EB and Rimm DL: Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86: 2259-2265, 1999. (Pubitemid 30010366)
17. Cheng HL, Liu HS, Lin YJ, et al: Co-expression of RON and MET is a prognostic indicator for patients with transitional cell carcinoma of the bladder. Br J Cancer 92: 1906-1914, 2005.
18. Borset M, Lien E, Espevik T, et al: Concomitant expression of hepatocyte growth factors carter factor and the receptor C-MET in human myeloma cell lines. J Biol Chem 271: 24655-24661, 1996.
19. Borset M, Hjorth-Hansen H, Seidel C, et al: Hepatocyte growth factor and its receptor c-Met in multiple myeloma. Blood 88: 3998-4004, 1996.
20. Bernstein E, Caudy AA, Hammond SM and Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409: 363-366, 2001.
21. Xie Z, JI C and Chen J: Construction and identification of recombinant plasmids containing short hairpin RNA targeting c-Met gene. Chinese Archives of Otolaryngology-Head and Neck Surgery 16: 251-254, 2009.
22. Wang S, Liu H, Ren L, et al: Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference. Neoplasia 10: 399-407, 2008.
23. Uemura K, Takao S and Aikou T: In vitro determination of basement membrane invasion predicts liver metastases in human gastro intestinalcarcinoma. Cancer Res 58: 3727-3731, 1998.
24. Jin M, He S, Worpel V, et al: Promotion of adhesion and migration of RPE cells to provisional extracellular matrices by TNF-α. Invest Ophthalmol Vis Sci 41: 4324-4332, 2000.
25. Wang SM, Zhu J, Pan LF and Liu YK: Inhibitory effect of dimeric β peptide on the recurrence and metastasis of hepatocellular carcinoma in vitro and in mice. World J Gastroenterol 14: 3054-3058, 2008.
26. Ramos-Nino ME, Blumen SR, Sabo-Attwood T, et al: HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1pathway. Am J Respir Cell Mol Biol 38: 209-217, 2008.
27. Chu SH, Yuan XH, Li ZQ, et al: C-Met antisense oligodeoxynucleotide inhibits growth of glioma cells. Surg neurol 65: 533-538, 2006.
28. Jiang Y, Xu W, Lu J, et al: Invasiveness of hepatocellular carcinoma celllines: contribution of hepatocyte growth factor, c-met, and transcription factor ets-1. Biochem Biophys Res Commun 286: 1123-1130, 2001.
29. Chu SH, Feng DF, Zhang H, et al: c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro. J Neurooncol 93: 183-189, 2009.
30. Seidel C, Borset M, Turesson I, et al: Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma: The Nordic Myeloma Study Group. Blood 91: 806-812, 1998.
31. Di Raimondo F, Azzaro MP, Palumbo G, et al: Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 85: 800-805, 2000.
32. Sezer O, Jakob C, Eucker J, et al: Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 66: 83-88, 2001.
33. Seidel C, Lenhoff S, Brabrand S, et al: Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol 119: 672-676, 2002.
34. Borset M, Lien E, Espevik T, et al: Concomitant expression of hepatocyte growth factors carter factor and the receptor C-MET in human myeloma cell lines. J Biol Chem 271: 24655-24661, 1996.
35. Tjin EP, Groen RW, Vogelzang I, et al: Function alanalysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 107: 760-768, 2006.
36. Chu SH, Feng DF, Zhang H, et al: c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro. J neurooncol 93: 183-189, 2009.
37. Ji CY, Xie ZN, Chen JC, et al: RNA interference targeting c-Met inhibits proliferation of human laryngeal carcinoma Hep-2 cell line in vitro and in its xenografts in nude mice. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 45: 61-67, 2010.
38. Aluigi M, Fogli M, Curti A, et al: Nucleofection is an effcient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem cells 24: 454-461, 2006.
39. Hov H, Tian E, Holien T, et al: c-Met signaling promotes IL-6 induced myeloma cell proliferation. Eur J Haematol 82: 277-287, 2009.
40. Du W, Hattori Y, Yamada T, et al: NK4, anantagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood 109: 3042-3049, 2007.
41. Stellrecht CM, Phillip CJ, Cervantes-Gomez F and Gandhi V: Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res 67: 9913-9920, 2007.
42. Munshi N, Jeay S, Li Y, et al: ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9: 1544-1553, 2010.
43. Uddin S, Hussain AR, Ahmed M, et al: Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Lab Invest 90: 1346-1356, 2010.
44. Derksen PW, de Gorter DJ, Meijer HP, et al: The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17: 764-774, 2003.
45. Kaufman SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cell by etoposide, camptothecin and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 49: 5870-5878, 1989.
46. Oltvai ZN, Milliman CL and Korsmeyer K: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
47. Mitsiades N, Mitsiades C, Poulaki V, et al: Biologic sequelae of nuclear factor-B blockade in multiple myeloma: therapeutic applications. Blood 99: 4079-4086, 2002.
48. Kitamura S, Kondo S, Shinomura Y, et al: Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers. Br J Cancer 83: 668-673, 2000.
49. Vande BI, Asosingh K, Allegaert V, et al: Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 18: 976-982, 2004.
50. Hov H, Holt RU, Ro TB, et al: A selective c-Met inhibitor blocks an autocrine hepatocyte growth factor loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res 10: 6686-6694, 2004.
51. Hazlehurst LA, Damiano JS, Buyuksal I, et al: Adhesion to fibronectin via β1 integrins regulates p27 kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). oncogene 19: 4319-4327, 2000.
52. Uchiyama H, Barut BA, Mohrbacher AF, et al: adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82: 3712-3720, 1993.
53. Lou X, Zhou Q, Yin Y, Zhou C and Shen Y: Inhibition of the met receptor tyrosine kinase signaling enhances the chemosensitivity of glioma cell lines to CDDP through activation of p38 MAPK pathway. Mol Cancer Ther 8: 1126-1136, 2009.
54. Chu SH, Ma YB, Feng DF, et al: c-Met antisense oligodeoxynucleotides increase sensitivity of human glioma cells to paclitaxel. Oncol Rep 24: 189-194, 2010.